Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imipenem

- PMLiVE

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

- PMLiVE

Merck & Co buys another immuno-oncology target

Will acquire German biotech Rigontec for €115m

- PMLiVE

Merck & Co’s anacetrapib data fails to generate much excitement

Treatment proves unable to reduce a composite outcome of major atherosclerotic events

- PMLiVE

Lynparza approval sets up tighter bout with PARP rivals

US regulator gives AZ the go-ahead for a new maintenance indication and formulation

Celgene building

Celgene steps back from $1bn Sutro acquisition

Instead opts for amended licensing deal with US biotech

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

- PMLiVE

European CTR implementation advances ethical assessment of clinical trials

Assessment process is being integrated into national laws

translational pharmacology medicine dose

Audit exposes gaps in pharma’s promises on trial transparency

Study group estimates nearly half of all clinical trials go unpublished

AstraZeneca AZ

Shock for AZ as MYSTIC trial stumbles at first hurdle

Combination fails to improve progression-free survival for lung cancer patients

- PMLiVE

Merck & Co’s Remicade biosimilar undercuts its US rivals

Its version will be 35% cheaper than J&J's originator product

- PMLiVE

Shake-up at GSK could claim antibiotics unit and UK facilities

The firm says its plans, which are expected to lead to 320 job cuts, are not related to Brexit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links